Bimagrumab: Trials and FDA Status
Bimagrumab is a activin receptor antibody (muscle-sparing). This page tracks its trials, sponsor and FDA status, with a dated source for each milestone.
Where it stands
- US status
- Investigational
- Phase
- Phase 2 (obesity)
- Sponsor
- Eli Lilly (earlier trials: Novartis)
- Expected FDA decision
- None announced
- no primary source states a date (checked 2 Oct 2026)
- Trial IDs (NCT)
- NCT03005288, NCT05616013, NCT06643728
Reported results
- 2021Phase 2 in type 2 diabetes with obesity (JAMA Netw Open 2021): body fat mass at week 48“Changes at week 48 for bimagrumab vs placebo were as follows: FM, -20.5% (-7.5 kg [80% CI, -8.3 to -6.6 kg]) vs -0.5% (-0.18 kg [80% CI, -0.99 to 0.63 kg])”pubmed.ncbi.nlm.nih.gov
- 2026Phase 2 BELIEVE with semaglutide (Nat Med 2026): weight change at week 48“The least squares mean absolute changes in body weight at week 48 were -9.3 kg (bimagrumab 30 mg kg-1), -14.2 kg (semaglutide 2.4 mg) and -17.8 kg (bimagrumab 30 mg kg-1 plus semaglutide 2.4 mg-that is, high-dose combination) versus -3.3 kg (placebo)”pubmed.ncbi.nlm.nih.gov
Company-reported figures are labelled as such. Results in a trial population may not match results elsewhere.
Milestones
- NCT06643728 (A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight; Phase 2): primary completion
- Published in Nature medicine (2026): Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial.
- NCT06643728 (A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight; Phase 2): study start
- NCT06643728 (A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight; Phase 2): first posted on ClinicalTrials.gov
- NCT05616013 (Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese; Phase 2): primary completion
- NCT05616013 (Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese; Phase 2): study start
- NCT05616013 (Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese; Phase 2): first posted on ClinicalTrials.gov
- Published in JAMA network open (2021): Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity: A Phase 2 Randomized Clinical Trial.
- NCT03005288 (Safety, Pharmacokinetics and Efficacy of Bimagrumab in Overweight and Obese Patients With Type 2 Diabetes; Phase 2): primary completion
- NCT03005288 (Safety, Pharmacokinetics and Efficacy of Bimagrumab in Overweight and Obese Patients With Type 2 Diabetes; Phase 2): study start
- NCT03005288 (Safety, Pharmacokinetics and Efficacy of Bimagrumab in Overweight and Obese Patients With Type 2 Diabetes; Phase 2): first posted on ClinicalTrials.gov (estimated)
What the bimagrumab registry entries specify
BELIEVE (NCT05616013) is titled as a randomised, double-blind, placebo-controlled study of intravenous bimagrumab, alone or with open-label subcutaneous semaglutide, in overweight or obese men and women.[2]
BELIEVE enrolled 507 participants.[2]
BELIEVE is completed: it started 2022-11-16 and reached primary completion on 2024-05-16.[2]
In the first type 2 diabetes study (NCT03005288), bimagrumab 10 mg/kg (up to 1200 mg) was given every 4 weeks until week 44, a 12-dose schedule.[1]
A newer trial (NCT06643728) gives bimagrumab together with tirzepatide, both subcutaneously.[3]
That combination trial enrolled 252 participants.[3]
It is active, not recruiting: it started 2024-10-21 and reached primary completion on 2026-01-16.[3]
Primary endpoints and trial length
The first type 2 diabetes trial's primary outcome was change in total body fat mass measured by DXA, not scale weight.[1]
The combination trial's primary outcome is percent change in body weight from baseline to week 24.[3]
From start to primary completion, BELIEVE spans 78 weeks and the tirzepatide combination trial 65 weeks.
Calculated from NCT05616013 start 2022-11-16, primary completion 2024-05-16, type ACTUAL; NCT06643728 start 2024-10-21, primary completion 2026-01-16, type ACTUAL. Formula: weeks = round((primary completion date - start date) / 7 days)
Published results
In the phase 2 type 2 diabetes trial, fat mass changed by -20.5% on bimagrumab against -0.5% on placebo at week 48.[4]
In BELIEVE, body weight at week 48 changed by -9.3 kg on bimagrumab alone, -14.2 kg on semaglutide alone and -17.8 kg on the high-dose combination, against -3.3 kg on placebo.[5]
Sources
- 1Safety, Pharmacokinetics and Efficacy of Bimagrumab in Overweight and Obese Patients With Type 2 Diabetes (NCT03005288)ClinicalTrials.gov (U.S. National Library of Medicine) · 2016clinicaltrials.govAccessed 2 Oct 2026
- 2Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese (NCT05616013)ClinicalTrials.gov (U.S. National Library of Medicine) · 2022clinicaltrials.govAccessed 2 Oct 2026
- 3A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight (NCT06643728)ClinicalTrials.gov (U.S. National Library of Medicine) · 2024clinicaltrials.govAccessed 2 Oct 2026
- 4Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity: A Phase 2 Randomized Clinical Trial.JAMA network open · 2021PMID 33439265Accessed 2 Oct 2026
- 5Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial.Nature medicine · 2026PMID 41772149Accessed 2 Oct 2026
Found an error? Report a correction.